Monthly Archives: June 2013

June 28 2013 | By Márcio Barra

The US Food and Drug Administration granted yesterday U.S. marketing approval for Rixubis, a genetically engineered protein (Coagulation Factor IX (Recombinant)) for the treatment of hemophilia B, made by Baxter International Inc. Hemophilia is an inherited blood clotting disorder that mainly affects males. Hemophilia B is one of two forms of the disease, and is caused by mutations in the Factor IX gene and leads to deficiency of Factor IX, causing excessive bleeding. The most common form is hemophilia A.

Read More

June 27 2013 | By Márcio Barra

GlaxoSmithKline announced today that it has obtained Breakthrough Therapy designation from the FDA for it’s in-development medicine Drisapersen, a late-stage treatment for Duchenne muscular dystrophy, a severely debilitating childhood neuromuscular disease that affects 1 in 3,500 live male births. This rare disease is caused by mutations in the dystrophin gene, resulting in the absence or defect of the dystrophin protein. Drisapersen is an antisense oligonucleotide, which induces exon skipping of exon 51 in cases where the child has dystrophin gene mutations due to an exon 51 skip. 

Read More

June 24 2013 | By Márcio Barrapharmu2

The institutional management of the Portuguese National Health Service is of public domain, with healthcare services being provided by public entities or by entities contracted by the Government. The National Health System also includes insurance companies and job related health subsystems. There is also a long standing tradition of private clinical practice by the physicians. While most of the Population is covered by the “potentially free” health system through the payment of taxes (following the Beveridge Model), the Portuguese Health System is currently a mix of both free and paid services.

Read More

June 21 2013 | By Márcio Barra

Frederick Curzon, 7th Earl Howe

Portugal isn’t the only EU member state looking on how to reduce state expenditure with medicines in the face of austerity. In the U.K., alongside the upcoming implementation of value-based pricing, linking the price of a drug to its value, in January 2014, the Department of Health announced today it’s plan to slash branded drug prices up to 20%. This is so that the U.K’s government can save 11.5 billion pounds ($18 billion) in the 2015-16 spending year.

Read More